ArticleInsights into imaging2026
Microstructural mapping of time-dependent diffusion MRI for predicting lymphovascular invasion in rectal cancer: a proof-of-concept investigation.
Article in Insights into imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
objectiveTo evaluate the value of time-dependent diffusion MRI (td-dMRI) derived microstructural parameters for predicting lymphovascular invasion (LVI) in rectal cancer. MATERIALS AND
methodsEighty-four resectable rectal cancer patients (stage T1, T2, T3a, T3b, and T4a) who underwent preoperative td-dMRI between March 2023 and June 2025 without neoadjuvant therapy were enrolled. Manual segmentation of tumors was performed by an experienced radiologist on each tumor's largest cross-sectional area. Microstructural parameters (intracellular volume fraction (ICVF), cell diameter, extracellular diffusivity and cellularity) were fitted using the limited spectrally edited diffusion model implemented in MATLAB (MathWorks, Inc.). Apparent diffusion coefficient (ADC) values at different diffusion times, relative ADC, ADC ratio, and MRI-reported extramural vascular invasion (EMVI) were also evaluated. Mann-Whitney U test was used to evaluate parameter differences between LVI-positive and LVI-negative. Logistic regression and receiver operating characteristic (ROC) curves (with DeLong test) were used to identify predictors of LVI and diagnostic performance.
resultsOf 84 participants (median age, 66 years; IQR, 60-70 years; 50 male), 30 were LVI-positive and 54 LVI-negative. ICVF, cell diameter, and cellularity were significantly higher in LVI-positive cases (all p < 0.05). MRI-EMVI (OR = 3.251), ICVF (OR = 8.137), and cellularity (OR = 1.159) were independent risk factors of LVI. The combined model integrating MRI-reported EMVI, cellularity, and ICVF achieved an area under the ROC curve (AUC) of 0.860, outperforming individual parameters including MRI-reported EMVI (AUC = 0.730), ICVF (AUC = 0.815), cellularity (AUC = 0.792) and ADC measurements (AUC = 0.631-0.710) (all p < 0.05).
conclusiontd-dMRI-derived parameters, especially ICVF and cellularity combined with MRI-reported EMVI, show potential as noninvasive biomarkers for LVI prediction in rectal cancer. CRITICAL RELEVANCE STATEMENT: This study develops a preoperative time-dependent diffusion MRI-based microstructure parameters model that diagnoses and predicts lymphovascular invasion of rectal cancer, improving diagnostic accuracy and advancing personalized treatment strategies in clinical radiology. KEY POINTS: The time-dependent diffusion MRI-derived microstructural parameters model and clinical data for predicting lymphovascular invasion in rectal cancer. The combined model outperforms single-modality models with 0.860 AUC and 96.3% specificity. The combined model provides a noninvasive, reliable tool for personalized lymphovascular invasion diagnosis and treatment planning.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.